TY - JOUR T1 - The clinical value of whole body Fluorine-18 Fluorodeoxyglucose PET/CT for detecting metastatic bladder cancer JF - Journal of Nuclear Medicine JO - J Nucl Med SP - 1408 LP - 1408 VL - 53 IS - supplement 1 AU - Zhongyi Yang AU - Yingjian Zhang Y1 - 2012/05/01 UR - http://jnm.snmjournals.org/content/53/supplement_1/1408.abstract N2 - 1408 Objectives The purpose of our study was to investigate the value of whole body Fluorine-18 2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography (PET)/computed tomography (CT) for detection of metastatic bladder cancer. Methods From December 2006 to August 2010, 60 bladder cancer patients (median age 60.5 years old, ranging from 32~96) underwent PET/CT from the proximal thighs to head. The accuracy of PET/CT was assessed using both organ-based and patient-based analyses. Lesions were validated by either biopsy or clinical follow-up for at least 6 months. Results One hundred and thirty-four suspicious lesions were identified in 60 eligible patients. Among these lesions, 4 secondary primary cancers (2 pancreatic cancers, 1 colonic and 1 nasopharyngeal cancer) were validated incidentally and the patients were treated in time. For the remaining 130 lesions, PET/CT detected 118 true positive lesions (sensitivity=95.9%). On patient-based analyses, the overall sensitivity and specificity were 87.1% and 89.7%, respectively. As for metastasis detection by PET/CT, there was no difference of sensitivity and specificity in patients with or without adjuvant treatment. Compared with conventional imaging modality, PET/CT correctly changed the management in 15 patients (25.0%). Conclusions PET/CT has excellent sensitivity and specificity in the detection of metastatic bladder cancer and provides additional diagnostic information ER -